Article Information
History
- April 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Farah M. Shurrab1,
- Fatima Humaira1,
- Enas S. Al-Absi1,
- Duaa W. Al-Sadeq1,2,
- Hamda Qotba3,
- Hadi. M. Yassine1,4,
- Laith J. Abu-Raddad5,6,7 and
- Gheyath K. Nasrallah1,4,*
- 1Biomedical Research Center, Qatar University, Doha 2713, Qatar
- 2College of Medicine, Member of QU Health, Qatar University, 2713, Doha, Qatar
- 3Department of Clinical Research, Primary Health Care Centers, 26555, Doha, Qatar
- 4Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713, Doha, Qatar
- 5Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
- 6World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
- 7Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, United States of America
- ↵*Correspond to:
Gheyath K. Nasrallah, Department of Biomedical Science, College of Health Sciences, Qatar University, Doha 2713, Qatar. Tel: +974 4403 4817, Email: gheyath.nasrallah{at}qu.edu.qa
Posted April 22, 2021.
No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
